RxDoctor Payments Data

Austen Slade, MD

Urology · Indianapolis, INNPI 1467815530

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Boston Scientific at 40.4% of the total. 2025 is the largest year on record at $41,085, more than ten times the $831 reported in 2019. Among urology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$73,381in general payments, 2019–2025

Across 260 payments — averaging $282.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$30K
  • Cook Incorporated$19K
  • Richard Wolf Medical Instruments Corp.$11K
  • Hologic Sales And Service, LLC$7K
  • Cook Medical LLC$2K
  • Laborie Medical Technologies Corp.$2K
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$16,86323%
  • Speaking & faculty fees$42,06657%
  • Travel & lodging$3,5045%
  • Food & beverage$10,94715%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,381 in reported general payments places this provider in the 95th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$148,535
Medicare patients
268
Services billed
1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron20$9,773
Trospium Chloride35$1,994
Tamsulosin Hcl125$1,069
Potassium Citrate ErPotassium Citrate14$882
Celecoxib30$643
Methenamine Hippurate13$527
Testosterone Cypionate12$513
Finasteride39$325
Alfuzosin Hcl ErAlfuzosin Hcl15$308
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$304
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim58$186
Ciprofloxacin Hcl25$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$68$9,77320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 urology providers in Indiana.

Other urology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →